S of moxifloxacin towards 900 aerobic and anaerobic surgical isolates from people

De Mundo Sirrus
Ir para: navegação, pesquisa

Antimicrob Agents mce medchemexpress Chemother 2000, 44:2225-2229. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T: A multicentre, open-label, randomized MEK162 COA comparative study of tigecycline versus ceftriaxone mce price sodium plus metronidazole to the treatment of hospitalized topics with difficult intra-abdominal infections. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B: DRAGON Study Workforce. Int J Antimicrob Agents 2009, 34(five):439-445. 200. Wagner C, Sauermann R, Joukhadar C: Principles of antibiotic penetration into abscess fluid. Pharmacology 2006, 78(one):1-10. 201. Bradford PA: Tigecycline: A first in class glycylcycline. Clin Microbiol Newsl 2004, 26:163-168. 202. Townsend ML, Pound MW, Drew RH: Tigecycline within the treatment of intricate intra-abdominal and sophisticated pores and skin and pores and skin composition infections. Ther Clin Chance Manag 2007, three(6):1059-1070. 203. Boucher HW, Wennersten CB, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25605552 Eliopoulos GM: In vitro pursuits on the glycylcycline GAR-936 versus gram-positive microbes. Antimicrob Brokers Chemother 2000, forty four:2225-2229. 204. Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Research Team: In vitro action of tigecycline against 2423 scientific isolates and comparison with the accessible interpretation breakpoints. Diagn Microbiol Infect Dis 2010, sixty six(two):187-194. 205. Giamarellou H, Poulakou G: Multidrug-resistant Gram-negative infections: What are the cure solutions? Medicines 2009, 69(fourteen):1879-1901. 206. Hirsch EB, Tam VH: Detection and treatment choices for Klebsiella pneumoniae carbapenemases (KPCs): an rising trigger of multidrugresistant an infection. J Antimicrob Chemother 2010, 65(six):1119-25. 207. Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J, Scatina J: Metabolic process, excretion, and pharmacokinetics of [14C]tigecycline, a firstin-class glycylcycline antibiotic, immediately after intravenous infusion to balanced male PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26011816 topics. Drug Metab Dispos 2007, 35(9):1543-53. 208. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, EllisGrosse EJ: Serum, tissue and system fluid concentrations of tigecycline following only one 100 mg dose. J Antimicrob Chemother 2006, 58(6):1221-9. 209. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP: Empiric treatment for secondary peritonitis: a pharmacodynamic investigation of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther 2007, 29(5):889-99.Sartelli et al. Globe Journal of Unexpected emergency Surgical procedures 2011, six:2 http://www.wjes.org/content/6/1/Page 28 of210. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, Tigecycline 301 Research Team: The efficacy and safety of tigecycline to the treatment method of difficult intra-abdominal infections: assessment of pooled scientific demo data. Clin Infect Dis 2005, forty one(Suppl five):S354-67. 211. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T: A multicentre, open-label, randomized comparative study of tigecycline compared to ceftriaxone sodium moreover metronidazole with the treatment of hospitalized topics with complicated intra-abdominal bacterial infections. Clin Microbiol Infect 2010, 16(eight):1274-81. 212. Yoshida M, Takada T, Kawarada Y, et al: Antimicrobial treatment for acute cholecystitis: Tokyo Suggestions. J Hepatobiliary Pancreat Surg 2007, 14:83-90.